UnitedHealth director Witty resigns, effective immediately

UnitedHealth Group Incorporated (NYSE:UNH) announced on Monday that Andrew Witty has resigned from his position as a director of the company, effective immediately. The resignation comes ahead of the company’s annual shareholder meeting scheduled for June 2, 2025. The news comes during a challenging period for the company’s stock, which has declined about 46% over the past six months, according to InvestingPro data.

Witty, who has served on the UnitedHealth board, will no longer be standing for re-election at the upcoming meeting. The company’s brief statement did not provide a reason for Witty’s departure nor did it mention a successor for his position on the board.

This change comes at a time when UnitedHealth, a leader in healthcare services with over $410 billion in annual revenue, continues to navigate the complex healthcare landscape. The company is well-known for providing health insurance services and a range of health products and services through its two distinct platforms, UnitedHealthcare and Optum. InvestingPro analysis shows the company maintains a strong financial health score, with robust profitability metrics and sustainable dividend payments spanning 33 consecutive years.

The information regarding Witty’s resignation was disclosed in a regulatory filing with the Securities and Exchange Commission on May 21, 2025. The filing ensures compliance with SEC regulations regarding the announcement of significant corporate governance changes.

As one of the largest companies in the health insurance sector, UnitedHealth Group’s corporate movements are closely watched by investors and industry analysts. However, the company has not indicated how Witty’s departure may affect its strategic direction or operations.

UnitedHealth Group, headquartered in Eden Prairie, Minnesota, continues to operate under the leadership of its remaining board members and executive team. The company has not yet publicly addressed the impact of Witty’s resignation on its governance or strategic planning.

This news report is based on a press release statement and aims to provide shareholders and the public with essential information regarding changes in UnitedHealth Group’s board of directors.

In other recent news, UnitedHealth Group has been the subject of various analyst evaluations and projections. HSBC downgraded UnitedHealth from Hold to Reduce, significantly lowering the price target to $270, citing concerns about the medical loss ratio and policy risks related to Optum Rx. In contrast, JPMorgan maintained an Overweight rating with a $405 target, suggesting that recent media scrutiny and market reactions might not fully reflect the company’s fundamentals. Wolfe Research also maintained an Outperform rating with a $390 target, focusing on the potential earnings per share reaching $21-$22 by 2025, though acknowledging uncertainties in the company’s commentary. Bernstein SocGen Group reiterated its Outperform rating with a $377 target, emphasizing Optum Health’s role in UnitedHealth’s value proposition and predicting a compound annual growth rate of around 8% over the next four years. UBS, while not issuing a stock rating, provided insights into healthcare insurance trends, highlighting the challenges employers face with rising healthcare costs, which could indirectly impact companies like UnitedHealth. These developments reflect a range of perspectives on UnitedHealth’s current and future financial performance, with analysts focusing on various aspects like earnings potential, strategic shifts, and sector challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.